|
Selected studies presentation for duloxetine |
||||||||||
| Study |
Inclusion criteria |
Age |
Percent male |
Duration (weeks) |
Treatment |
Dosage (mg/day) |
Patients per arm |
Effect size (SD) |
Response (%) |
Dropouts (%) |
|
|
||||||||||
| Goldstein et al. [9] |
DSM-IV, Age 18–65 HAM-D17 ≥ 15, CGI-S ≥ 4 |
42 |
0.34 |
8 |
Duloxetine Placebo |
40–120 |
70 70 |
-0.3(0.03) |
0.64 0.48 |
0.34 0.34 |
| Detke et al. [10] |
DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 |
42 |
0.33 |
9 |
Duloxetine Placebo |
60 |
123 122 |
-0.6(0.02) |
0.62 0.29 |
|
| Detke et al. [12] |
DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 |
41 |
0.31 |
9 |
Duloxetine Placebo |
60 |
128 139 |
-0.2(0.02) |
0.65 0.42 |
0.39 0.35 |
| Detke et al. [13] |
DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 |
45 43 |
0.26 0.25 |
8 |
Duloxetine Duloxetine Placebo |
80 120 |
95 93 93 |
-0.3(0.02) -0.6(0.02) |
0.65 0.71 0.44 |
0.13 0.10 0.19 |
| Goldstein et al. [14] |
DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 |
41 41 |
0.4 0.38 |
8 |
Duloxetine Duloxetine Placebo |
40 80 |
86 91 89 |
-0.4(0.02) -0.5(0.02) |
0.54 0.60 0.30 |
0.36 0.42 0.42 |
| Greist et al. [4] Falissard et al. [3] |
DSM-IV, Age ≥ 18 |
8 |
Duloxetine Placebo |
120 |
82 75 |
-0.1(0.03) |
||||
| Greist et al. [4] Falissard et al. [3] |
DSM-IV, Age ≥ 18 |
8 |
Duloxetine Duloxetine Placebo |
40 80 |
91 84 90 |
-0.2(0.02) -0.4(0.02) |
||||
| Greist et al. [4] Falissard et al. [3] |
DSM-IV, Age ≥ 18 |
8 |
Duloxetine Duloxetine Placebo |
80 120 |
93 103 99 |
-0.3(0.02) -0.3(0.02) |
||||
| Brannan et al. [5] |
DSM-IV, Age ≥ 18 HAM-D17 ≥ 15, CGI-S ≥ 4 |
41 |
0.35 |
9 |
Duloxetine Placebo |
60 |
141 141 |
-0.2(0.02) |
0.42 0.40 |
0.16 0.09 |
| Globally |
42 (1) |
0.33 |
8 (0.4) |
Duloxetine Placebo |
20–120 |
1280 918 |
-0.29(0.05) |
0.58(0.09) ** |
-0.02(0.16) ** |
|
|
** Log Odds ratios (SD) | ||||||||||
Eckert and Lançon BMC Psychiatry 2006 6:30 doi:10.1186/1471-244X-6-30 |
||||||||||